|Project Title||Principal Investigator||Institution|
|Development of a high-content neuronal assay to screen therapeutics for the treatment of cognitive dysfunction in autism spectrum disorders||Bear, Mark||Massachusetts Institute of Technology|
|Mice lacking Shank postsynaptic scaffolds as an animal model of autism||Sheng, Morgan||Massachusetts Institute of Technology|
|Neural and cognitive mechanisms of autism||Sur, Mriganka||Massachusetts Institute of Technology|
|Regulation of synaptogenesis by cyclin-dependent kinase 5||Tsai, Li-Huei||Massachusetts Institute of Technology|
|Synaptic and circuitry mechanisms of repetitive behaviors in autism||Feng, Guoping||Massachusetts Institute of Technology|
|Using Drosophila to model the synaptic function of the autism-linked NHE9||Littleton, J. Troy||Massachusetts Institute of Technology|
|The role of SHANK3 in autism spectrum disorders||Buxbaum, Joseph||Mount Sinai School of Medicine|
|A preclinical model for determining the role of AVPR1A in autism spectrum disorders||Charles, Rhonda||Mount Sinai School of Medicine|
|Animal models of neuropsychiatric disorders||Crawley, Jacqueline||National Institutes of Health (NIH)|
|Studies on protein synthesis and long-term adaptive responses in the CNS||Smith, Carolyn||National Institutes of Health (NIH)|
|Synaptic plasticity, memory and social behavior||Chevere-Torres, Itzamarie||New York University|
|The integration of interneurons into cortical microcircuits||Fishell, Gordon||New York University School of Medicine|
|Using iPS cells to study genetically defined forms with autism||Dolmetsch, Ricardo||Stanford University|
|Function and dysfunction of neuroligins||Sudhof, Thomas||Stanford University|
|Role of L-type calcium channels in hippocampal neuronal network activity||Owen, Scott||Stanford University|
|Serotonin, autism, and investigating cell types for CNS disorders||Dougherty, Joseph||The Rockefeller University|
|A proposal to define cells and circuits impacted in autism spectrum disorders||Heintz, Nathaniel||The Rockefeller University|
|A novel cell-based assay for autism research and drug discovery||Restifo, Linda||University of Arizona|
|Primate models of autism||Amaral, David||University of California, Davis|
|A non-human primate autism model based on maternal immune activation||Patterson, Paul||University of California, Davis|
|CNTNAP2 in a behavioral model of autism||White, Stephanie||University of California, Los Angeles|
|Functional analysis of neurexin IV in Drosophila||Zipursky, Larry||University of California, Los Angeles|
|Neurogenomics in a model for procedural learning||Hilliard, Austin||University of California, Los Angeles|
|Dissecting the neural control of social attachment||Shah, Nirao||University of California, San Francisco|
|Role of a novel Wnt pathway in autism spectrum disorders||Reichardt, Louis||University of California, San Francisco|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.